Regencell Bioscience Holdings Stock Market Capitalization
| RGC Stock | USD 41.00 17.63 30.07% |
Regencell Bioscience Holdings fundamentals help investors to digest information that contributes to Regencell Bioscience's financial success or failures. It also enables traders to predict the movement of Regencell Stock. The fundamental analysis module provides a way to measure Regencell Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regencell Bioscience stock.
Regencell |
Regencell Bioscience Holdings Company Market Capitalization Analysis
Regencell Bioscience's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Regencell Bioscience Market Capitalization | 762.95 M |
Most of Regencell Bioscience's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regencell Bioscience Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Regencell Bioscience Holdings is about 762.95 M. This is 94.1% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The market capitalization for all United States stocks is 95.99% higher than that of the company.
Regencell Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regencell Bioscience's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regencell Bioscience could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics of similar companies.Regencell Bioscience is currently under evaluation in market capitalization category among its peers.
Regencell Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 745.38 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Shares Owned By Insiders | 93.83 % | ||||
| Shares Owned By Institutions | 0.29 % | ||||
| Number Of Shares Shorted | 18.18 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 91.65 X | ||||
| EBITDA | (3.62 M) | ||||
| Net Income | (4.36 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 85.74 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (4 M) | ||||
| Short Ratio | 0.32 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Price To Earnings To Growth | 2.15 X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.62 | ||||
| Market Capitalization | 762.95 M | ||||
| Total Asset | 8.44 M | ||||
| Retained Earnings | (21.62 M) | ||||
| Working Capital | 7.92 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
| Five Year Return | 4.37 % | ||||
| Net Asset | 8.44 M |
About Regencell Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regencell Bioscience Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regencell Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regencell Bioscience Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Regencell Bioscience Piotroski F Score and Regencell Bioscience Altman Z Score analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.